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Carotid Artery Stenting
Before Cardiac Surgery
A Promising Path Down a Muddy Road?*
William Anthony Gray, MD
New York, New York
Things alter for the worse spontaneously,
if they be not altered for the better designedly
—Francis Bacon (1)
The management of synchronous carotid disease and coro-
nary or valvular disease requiring surgical repair has been a
constant challenge to clinicians for decades and for a variety
of reasons. First, although it is a vexing problem, it is
relatively infrequent, such that any single institution/
operator experience in management will always be clouded
by “the last case I did” syndrome, more reflective than
definitive. Second, even in patients without carotid stenosis,
the risk of stroke inherent in cardiac surgery from other
sources (atheroembolic from aortic manipulation, air em-
boli, and so on) clouds the assessment of the neurological
“natural” history of the unoperated carotid stenosis in this
setting. However, it seems clear enough that the patient
with symptomatic carotid disease is at most risk and requires
further management consideration, but that most asymp-
tomatic patients with unilateral disease can withstand a
See page 1190
cardiac operation with little increase in overall stroke risk
and, therefore, should not be subjected to carotid revascu-
larization risks (2). Next, the published database that
generally helps guide such decisions in practice comprises
largely single-center reports, and usually retrospectively
analyzed. A recent Cochrane attempt to review all the pub-
lished randomized data on the subject could not be completed,
because there were no such studies in existence (3). Further
complicating matters, the therapeutic approaches are multi-
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Road Medical.ple—carotid endarterectomy (CEA) can be done either before,
after, or combined with cardiac surgery, which might be on- or
off-pump—and this further dilutes an already shallow pool of
data. And lastly, the data that are available are of mixed
quality with regard to ascertainment of important clinical
events (always an issue in retrospective assessments), selec-
tion of patients for any given approach (such bias is inherent
in the practice of medicine absent the “guidance” of an
investigational protocol), and almost uniformly lack a con-
trol group (even nonrandomized).
Into this tar pit wades the relative newcomer on the
block, carotid artery stenting (CAS). The appeal of CAS as
an alternative to CEA is obvious in patients with cardiac
disease: the lack of anesthesia and physiological surgical
“stress” in an obviously vulnerable population, often with
multiple comorbidities and organ involvement. In support
of this speculative advantage, periprocedural outcomes from
the randomized SAPPHIRE (Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy) trial in symptomatic high surgical risk patients
trended better in CAS compared with CEA, 2.1% versus
9.3% (p  0.18) (4). In addition, the recent National
Institutes of Health CREST (Carotid Revascularization
Endarterectomy versus Stenting Trial) randomized trial
results, representing standard surgical risk patients enrolled
from 2000 to 2008, demonstrated no differences between
CEA and CAS in 1,321 symptomatic patients for the
primary endpoint of death, stroke, and myocardial infarc-
tion (MI), 5.4  0.9% versus 6.7  1.0% (p  0. 57),
respectively (5).
On this encouraging background, in this issue of JACC:
Cardiovascular Interventions, Van der Heyden et al. (6)
report the outcomes of patients with strictly symptomatic
carotid stenosis requiring cardiac surgery, the first prospec-
tive study to singularly address the critical group in question.
We must be mindful that, although it spanned 10 years, it
is nevertheless a small study and therefore subject to the
statistical vagaries that can confound results, so conclusions
drawn should be appropriately circumspect. Consecutive
patient outcomes were prospectively gathered from 1998 to
2008 in this single-arm study at an expert high-volume
center, and both MIs and strokes appear to be appropriately
ascertained. An embolic protection device (EPD) was used
when available after 2002, but representative of only one-
half of the treated population—important because meta-
analyses have suggested that stroke outcomes are likely
better with EPD use in CAS, although no large-scale
randomized data exist (7). Specific to this analysis was the
helpful reporting of events temporally and specifically re-
lated either to the CAS or to the cardiac surgery, most of
which was done on-pump. Employing CAS, the authors
demonstrated a remarkably low rate (1.5%) of MI in this
group of patients with high-risk coronary anatomy and an
acceptable rate of stroke (7.0%), all of which were minor
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1198(and 1 of which was contralateral, presumably due to aortic
arch source during access attempts). There were only 2
additional events occurring after surgery—a death and a
major stroke—for a combined rate of death, stroke, and
myocardial infarction of 12.3%. Not surprisingly, the 5-year
morbidity and mortality in this group was substantial, most
of it vascular, and worse in elderly patients.
Do these results reflect the current outcomes expected
from high-surgical-risk populations undergoing CAS? A
fair question, because results in the United States for CAS
have shown a dramatic improvement over the past decade,
and complications have more than halved since the initial
SAPPHIRE (4) and ARCHeR (ACCULINK for Revascu-
larization of Carotids in High Risk Patients) studies (8). The
death and stroke rate of 7.0% reported here is higher than the
2 most recent and largest prospective multicenter experiences
with CAS in symptomatic patients: the combined CAPTURE 2
(Carotid ACCULINK/ACCUNET Post-approval Trial to
Uncover Rare Events)/EXACT (Emboshield and Xact Post
Approval Carotid Stent Trial) single-arm study outcomes in
high surgical risk patients, and the CREST study in
standard surgical risk patients, which were 5.7% and 6.0%,
respectively. This might be related to the lack of EPD in the
first one-half of the patients, an evolving technique over 10
years in a novel therapy, and the small numbers of subjects
(i.e., 1 less stroke event and the rate becomes more contem-
porary). To the positive, all CAS-related strokes were
minor, and it has been observed that most of these will
resolve significantly and leave little if any residual neurolog-
ical deficit (9,10).
That proviso aside, some answers to important questions
might be forthcoming after considering this well-collected and
clinically relevant data in the clinical management of the
patient with symptomatic carotid disease requiring cardiac
surgery. Is CAS better than no carotid intervention at all (i.e.,
have we satisfied Bacon’s imperative to have “altered for the
better designedly?”). What is the relative value of CAS versus
CEA in the management of these patients?
Before making any comparison of these data with histor-
ical unoperated or CEA outcomes, 2 important caveats
must be considered. First, there are very limited data with
regard to prophylactic CEA in a purely symptomatic pop-
ulation, and to compare mixed populations that include
significant numbers of asymptomatic patients is not a sound
approach, because results would be expected to differ be-
tween these populations. Second, most prior studies have
not been as vigilant about ascertaining related events as Van
der Heyden et al. (6), specifically assessing with neurological
evaluation before and after the procedures or documenting
MI by prospectively checking enzyme and electrocardio-
grams. It has been amply demonstrated that the prospective
evaluation of stroke in patients undergoing isolated CEA
results in the trebling of strokes reported, mostly by picking
up the minor strokes that otherwise go unnoticed byoperators (11,12). Furthermore, the distinction between
major and minor stroke has not typically been made in prior
published reports on the subject. It is noteworthy that in the
present study there was only 1 major stroke (after cardiac
surgery), making the combined major stroke rate and death
approximately 1.8% and comparing exceptionally well to the
rate of 14.2% in historical/retrospective data, which pre-
sumably reported primarily major strokes (13). It has also
been recently shown that CEA and CAS perioperative MI
is a predictor of long-term mortality, regardless of size of the
event (10), so that this is an important but generally
undercounted/reported outcome. With regard to the out-
comes with staged CAS and cardiac surgery seen here, they
do in fact seem to be at least comparable to the stroke rate
of 8.5% in unoperated symptomatic carotid disease under-
going cardiac surgery and to the rate of death and stroke in
staged CEA and cardiac surgery, both of which might be
underestimated for the reasons given previously (14,15).
It is tempting to suggest that CAS might be the preferred
treatment in these cases, given the previously enumerated
problems in comparisons with historical CEA outcomes,
with the observed improvements in CAS outcomes over
time and with routine EPD availability, and with the lack of
associated major stroke in CAS. However, lacking a direct
randomized comparison and given the difficult-to-compare
historical data, it is not possible to make any definitive
statements about the relative merits of 1 approach over the
other. On the basis of the results reported by Van der
Heyden et al. (6), we can conclude that a well-performed
CAS by experienced operators is likely to be at least on par
with CEA as a staged pre-treatment strategy and likely
better than nothing at all, for managing symptomatic
patients with carotid disease undergoing cardiac surgery.
Perhaps even Bacon would be satisfied.
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